Beta Bionics Q2 Revenue Jumps 38%, Gross Margin Expands; Raises Full-Year Margin Outlook
BBNX sits 76% above its 52-week low of $8.8.
Summary
Beta Bionics reported Q2 2026 revenue of $32 million (+38% YoY), raised full-year gross margin guidance, and highlighted pipeline progress including a pivotal type 2 diabetes trial. Cash of $225 million funds operations into 2028.
Key Events · Earnings and Guidance · BBNX
-
Q2 Revenue Up 38% to $32M
Net sales reached $32.0 million, driven by a 153% increase in the Pharmacy Benefit Plan channel to $11.6 million. DME channel sales grew 9% to $20.4 million.
-
Gross Margin Expands to 59%
Gross margin improved 524 basis points year-over-year to 59.0%, reflecting favorable product mix and operating leverage. Full-year gross margin guidance was raised to 58.5%-59.5%.
-
Full-Year Revenue Guidance Maintained
The company reiterated 2026 revenue guidance of $131-$136 million, implying ~120% growth at the midpoint, with no change to PBP channel mix expectations.
-
Pipeline Advances: Type 2 Trial and Mint Pump
Enrollment began for a pivotal U.S. trial of iLet in type 2 diabetes, with potential label expansion by mid-2027. Mint patch pump commercialization is targeted for end of Q2 2027, subject to FDA clearance.
Analysis · BBNX · Industrial Applications And Services
Beta Bionics delivered strong Q2 results with revenue up 38% to $32 million, driven by a 153% surge in pharmacy channel sales. Gross margin expanded 524 basis points to 59%, and the company raised its full-year gross margin guidance. Operating losses widened on higher commercial investment, but the $225 million cash position provides runway into 2028. The results come amid a securities investigation announced in June, making the strong operational performance a potential counterweight to legal overhang.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.7% of the 1739 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBNX was trading at $15.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $676M. The 52-week trading range was $8.80 to $32.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.